Andy Porter Biography and Net Worth

Insider of Relay Therapeutics

As Chief Administrative Officer, Andy Porter is responsible for overseeing HR, facilities and real estate, internal communications and special projects. Prior to Relay Therapeutics, Andy served for more than five years as the chief people officer at the Broad Institute of MIT and Harvard, where he was responsible for leading the HR strategy for a community of 4,000 people, as well as leading space planning and design for Broad’s campus in Cambridge. Before that, he was vice president of human resources and organizational development at Merrimack Pharmaceuticals, and held various roles at Dyax Corp. and Harvard-affiliated hospitals.

Andy is a member of the board of directors for the Northeast Human Resources Association and is a frequent speaker at industry conferences. He has also spent time outside of his full-time roles teaching as an adjunct professor at Massachusetts College of Pharmacy and Health Science.

Andy holds a B.S. in organizational psychology from Bridgewater State University and an M.S. in organization development from American University.

What is Andy Porter's net worth?: The estimated net worth of Andy Porter is at least $230,562.22 as of October 28th, 2022. Mr. Porter owns 45,164 shares of Relay Therapeutics stock worth more than $230,562 as of November 17th. This net worth estimate does not reflect any other assets that Mr. Porter may own. Learn More about Andy Porter's net worth.
How do I contact Andy Porter?: The corporate mailing address for Mr. Porter and other Relay Therapeutics executives is 399 BINNEY STREET 2ND FLOOR, CAMBRIDGE MA, 02139. Relay Therapeutics can also be reached via phone at 617-370-8837 and via email at [email protected]. Learn More on Andy Porter's contact information.
Has Andy Porter been buying or selling shares of Relay Therapeutics?: Andy Porter has not been actively trading shares of Relay Therapeutics during the last quarter. Most recently, Andy Porter sold 448 shares of the business's stock in a transaction on Friday, October 28th. The shares were sold at an average price of $21.54, for a transaction totalling $9,649.92. Following the completion of the sale, the insider now directly owns 45,164 shares of the company's stock, valued at $972,832.56. Learn More on Andy Porter's trading history.
Who are Relay Therapeutics' active insiders?: Relay Therapeutics' insider roster includes Brian Adams (General Counsel), Donald Bergstrom (Insider), Thomas Catinazzo (SVP), and Andy Porter (Insider). Learn More on Relay Therapeutics' active insiders.
Are insiders buying or selling shares of Relay Therapeutics?: In the last twelve months, insiders at the sold shares 18 times. They sold a total of 141,822 shares worth more than $1,108,841.14. The most recent insider tranaction occured on October, 28th when insider Peter Rahmer sold 1,621 shares worth more than $9,823.26. Insiders at Relay Therapeutics own 4.3% of the company. Learn More about insider trades at Relay Therapeutics.
Information on this page was last updated on 10/28/2024.

Andy Porter Insider Trading History at Relay Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/28/2022	Sell	448	$21.54	$9,649.92	45,164
7/28/2022	Sell	452	$21.27	$9,614.04	45,871
6/27/2022	Sell	265	$20.31	$5,382.15	46,323
3/29/2022	Sell	294	$29.87	$8,781.78
12/27/2021	Sell	260	$33.10	$8,606.00

Andy Porter Buying and Selling Activity at Relay Therapeutics

Relay Therapeutics Company Overview

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $5.11

$5.03

$5.63

50 Day Range

MA: $6.71

$5.11

$9.51

2 Week Range

Now: $5.11

$5.03

$12.14

Volume

1,925,087 shs

Average Volume

1,251,957 shs

Market Capitalization

$854.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67

Urgent: This election is rigged

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.